We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Bacterial Pneumonia Responds Best to an Antibiotic and Steroid Cocktail

By LabMedica International staff writers
Posted on 21 Oct 2008
Researchers working with a mouse model of bacterial pneumonia have found that treatment with a combination of antibiotic and corticosteroid was more effective than antibiotic treatment alone in curing the disease.

Mycoplasma pneumoniae causes a relatively benign type of respiratory disease that accounts for 20 to 30% of all community-acquired pneumonia cases. More...
Traditionally, infections with M. pneumoniae are treated with antibiotics. However, while this treatment eliminates the causative agent of the respiratory disease, it does not aid in reducing inflammation and swelling in the lungs.

In a study published in the October 15, 2008, issue of the Journal of Infectious Diseases, investigators at the University of Texas Southwestern Medical Center (Dallas, USA) combined traditional antibiotic treatment (in this study clarithromycin) to kill the pathogenic bacteria with corticosteroid treatment to reduce inflammation.

Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex. They are involved in a wide range of physiologic systems such as stress response, immune response and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior. The steroid used in this study was dexamethasone.

Mice were infected with M. pneumoniae and then separated into separate treatment groups. Different groups were treated with clarithromycin, dexamethasone, combined clarithromycin/dexamethasone, or a placebo daily. The mice were evaluated at the start of the therapy and after one, three, and six days of treatment.

Results showed that while antibiotic therapy with clarithromycin had the greatest effect on reducing concentrations of M. pneumoniae, combination antibiotic/steroid therapy had the greatest effect on decreasing levels of cytokines and chemokines as well as reducing lung inflammation.

"It turns out that the group that got both the antibiotic and the steroids did the best,” said senior author Dr. Robert Hardy, associate professor of internal medicine and pediatrics at the University of Texas Southwestern Medical Center. "The inflammation in their lungs got significantly better. Some people might think that if you give steroids, it would counteract the effect of the antibiotic, but it turns out you need the antibiotic to kill the bug and the steroid to make the inflammation in the lung from the infection get better. The steroids do not kill the bugs, but they do help restore health.”

Related Links:
University of Texas Southwestern Medical Center



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.